Current findings for recurring mutations in acute myeloid leukemia.

J Hematol Oncol · 2011 · PMC3180439 · PMID 21917154

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

Compared with C/EBPα-wild-type patients, patients with C/EBPα mutations showed a trend for a better CR rate (93% vs. 77%; p = 0.06) and significantly higher 5-year rates of EFS (55% vs. 17%; p < 0.001), DFS (53% vs. 23%; p = 0.001) and OS (58% vs. 27%; p = 0.002) [ 80 ] (Table 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.